Phase I and pharmacokinetic study of intraperitoneal topotecan

Investigational New Drugs

Volumn 16, Issue 2, 1998, Pages 147-153

  Plaxe, Steven C ^a   Christen, Randolph D ^b   O'Quigley, John ^c   Braly, Patricia S ^a   Freddo, James L ^a   McClay, Edward ^b   Heath, Dennis ^b   Howell, Stephen B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Camptothecin analogs; Chemotherapy; Regional drug delivery

Indexed keywords

TOPOTECAN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FEMALE; FEVER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKOPENIA; NEUTROPENIA; OVARY CARCINOMA; PERITONEUM TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MIDDLE AGED; TOPOTECAN;

EID: 0031730898     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006045125018     Document Type: Article

References (18)

1. Swisher EM, Mutch DG, Rader JS, Elbanedary A, Herzorg TJ: Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynegologic Oncol 66: 480-486, 1997
2. Ten Bokkel Huinink W, Gore M, Carmichael J, Gordan A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC, Heron JF: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15: 2183-2193, 1997
3. Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, Van Belle S et al.: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14: 3056-3061, 1996
4. Rowinsky E, Grochow L, Hendricks C, Sartonus S, Ettinger D, McGuire W, Forastiere A, Hurowitz L, Easter V, Doehower R: Phase I and pharmacologic study of topotecan (SK & F 104864): a novel topoisomerase I inhibitor. Proc ASCO 10: 93, 1992
5. Sirott MN, Saltz L, Young C, Tong W, Trochanowski B, Niedzwiecki D, Toomasi F, Kelsen D: Phase I and clinical pharmacologic study of intravenous topotecan (T). Proc ASCO 10: 104, 1991
6. Kudelka AP, Tresukosol D, Edwards CL, Freedman RS, Levenback C, Chantarawiroj P, Gonzalez de Leon C, Kim EE, Madden T, Wallin B, Hord M, Verschragen C, Raber M, Kavanagh J: Phase II study of intravenous topotecan as a 5-day infusion for refractory ovarian carcinoma. J Clin Oncol 14: 1552-1557, 1996
7. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B, Adelson MD, Hoskins WJ: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950-1955, 1996
8. Myers CE, Collins JM: Pharmacology of intraperitoneal chemotherapy. Cancer Invest 1(5): 395-407, 1983
9. Herben VMM, Ten Bokkel Huinink WW, Beijnen JH: Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 31: 85-102, 1996
10. Wall J, Havlin K, Burris H, Weiss G, Brown T, Brown J, Kuhn J, Johnson R, Mann W, Webb D, Von Hoff D: Phase I study of SK & F 104864: a novel topoisomerase inhibitor. Proc ASCO 9: 86, 1990
11. O'Quigley J, Chevret SS: Methods for dose finding studies in cancer clinical trials. Statistics in Medicine 10: 1647-1664, 1991
12. O'Quigley J, Pepe M, Fisher L: Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46: 33-48, 1990
13. O'Quigley J: Estimating the probability of toxicity at the recommended dose following a phase I clinical study in cancer. Biometrics (in press)
14. Markman M, Howell SB, Lucas WE, Pfeifle CE, Green M: Combination intraperitoneal chemotherapy with cisplatin, cytarabine and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol 2: 1321-1326, 1984
15. Beijnen JH, Smith BR, Keijer WJ, Van Gijn R, Ten Bokkel Huinink WW, Vlasveld LT, Rodenhuis S, Underberg WJM: High-performance liquid chromatographic of the new antitumor drug SKF104864-A (NSC 606699) in plasma. J Pharmacol Biomed Anal 8: 789-794, 1990
16. Van Warmerdam LJC, Ten Bokkel Huinink WW, Rodenhuis S et al.: Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion (published erratum appears in J Clin Oncol 14: 689, 1996). J Clin Oncol 13: 1768-1776, 1995
17. O'Reilly S, Fleming GF, Baker SD, Walczak JR, Bookman MA, McGuire III WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK: Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a gynecologic oncology group study. J Clin Oncol 15: 177-186, 1997
18. Rowinsky E, Grochow L, Kaufmann S et al.: Sequence-dependent effects of topotecan and cisplatin in a phase I and pharmacokinetic study. Proc ASCO 13: 142, 1994